Remix Therapeutics agreed to go public through a reverse merger with Passage Bio, with the combined company expected to trade under the Remix name and the ticker RMTX. Remix investors are slated to own about 93% of the new entity, while Passage shareholders receive 7%, plus a contingent value right tied to the performance of licensed pediatric gene therapy assets.